Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Swapnil Rajurkar"'
Autor:
Xuan Ge, Susan E. Yost, Jin Sun Lee, Paul H. Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Samuel Chung, Christina Yeon, Daphne Stewart, Daneng Li, Swapnil Rajurkar, George Somlo, Joanne Mortimer, James Waisman, Yuan Yuan
Publikováno v:
Cancers; Volume 14; Issue 17; Pages: 4279
This study investigated the safety and antitumor activity of aromatase inhibitors (AI) with immune checkpoint inhibitor (ICI) pembrolizumab in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95c7021ebe5c7ffe641768e41f906ce
Autor:
Susan E. Yost, Yuan Yuan, Christopher Ruel, Aileen Tang, Colt Egelston, Niki Patel, Norma Martinez, Jin Sun Lee, Swapnil Rajurkar, Joanne E. Mortimer, Simran Padam, Christina Yeon, Paul Frankel, Cary A. Presant, Mina S. Sedrak, Jana Portnow, Peter P. Lee
Publikováno v:
Cancer Research. 80:P3-11
Background: The combination of CDK4/6 inhibitor and aromatase inhibitor is the current standard of care therapy for patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC). Single agent immune check point inhibitor (ICI) pembrol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f4f48ada993bd6413ba477a869268e4
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-04
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-04
Autor:
Sravani Ramisetty, Prakash Kulkarni, Supriyo Bhattacharya, Arin Nam, Sharad S. Singhal, Linlin Guo, Tamara Mirzapoiazova, Bolot Mambetsariev, Sandeep Mittan, Jyoti Malhotra, Evan Pisick, Shanmuga Subbiah, Swapnil Rajurkar, Erminia Massarelli, Ravi Salgia, Atish Mohanty
Publikováno v:
Journal of Clinical Medicine. 12:599
Translational research in medicine, defined as the transfer of knowledge and discovery from the basic sciences to the clinic, is typically achieved through interactions between members across scientific disciplines to overcome the traditional silos w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4edc3ac11612debb4576b4147b765315
https://doi.org/10.3390/jcm12020599
https://doi.org/10.3390/jcm12020599
Autor:
Prakash Kulkarni, Atish Mohanty, Supriyo Bhattacharya, Sharad Singhal, Linlin Guo, Sravani Ramisetty, Tamara Mirzapoiazova, Bolot Mambetsariev, Sandeep Mittan, Jyoti Malhotra, Naveen Gupta, Pauline Kim, Razmig Babikian, Swapnil Rajurkar, Shanmuga Subbiah, Tingting Tan, Danny Nguyen, Amartej Merla, Sudarsan V. Kollimuttathuillam, Tanyanika Phillips, Peter Baik, Bradford Tan, Pankaj Vashi, Sagun Shrestha, Benjamin Leach, Ruchi Garg, Patricia L. Rich, F. Marc Stewart, Evan Pisick, Ravi Salgia
Publikováno v:
Journal of Clinical Medicine. 11:5701
Drug resistance remains one of the major impediments to treating cancer. Although many patients respond well initially, resistance to therapy typically ensues. Several confounding factors appear to contribute to this challenge. Here, we first discuss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfd79fef4220ccb4db25ce09d59cb5de
https://doi.org/10.3390/jcm11195701
https://doi.org/10.3390/jcm11195701
Autor:
Swapnil Rajurkar, TingTing Tan, Isa Mambetsariev, Ravi Salgia, Benjamin I. Leach, Prakash Kulkarni, Rebecca Pharaon
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 1870, p 1870 (2020)
Journal of Clinical Medicine
Journal of Clinical Medicine
Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced with the identification of various key oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0c361ca52fa1d5f6e396ace21b80dd8
https://www.mdpi.com/2077-0383/9/6/1870
https://www.mdpi.com/2077-0383/9/6/1870
Publikováno v:
Medicine. 99:e22323
Rationale Patients reporting high PD-L1 expression have shown to respond well to immunotherapy; however, some patients develop hyperprogressive disease upon initiation of immune checkpoint inhibitors. We report a patient with lung cancer and 100% PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::116b768ff94a8b59b7d66e6d1507ef0c
https://doi.org/10.1097/md.0000000000022323
https://doi.org/10.1097/md.0000000000022323
Autor:
Allan Hallquist, Carl Rogaston Willis, Michael R. Chernick, Linda D. Bosserman, Franklyn G Prendergast, James Rutledge, Mathieu Perree, Howard D. Homesley, Martin Fleisher, Dirk C. Davidson, Matthew Burrell, Roy S. Herbst, Audrey Garrett, Manuel Penalver, Swapnil Rajurkar, Misagh Karimi, Steven Strickland, Emery M. Salom, Karl Rogers, Cary A. Presant, Anastasios Raptis
Publikováno v:
Cancer Research. 72:3901-3905
A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83d4df2d6d01f0b83cd128ca31c2fc5
https://doi.org/10.1158/0008-5472.can-12-0681
https://doi.org/10.1158/0008-5472.can-12-0681
Autor:
Swapnil Rajurkar, Allan Hallquist, Dirk C. Davidson, Karl Rogers, Debbee Malouf, Cary A. Presant, Linda D. Bosserman, Michael R. Chernick
Publikováno v:
Cancer. 118:4877-4883
BACKGROUND: An observational prospective nonblinded clinical trial was performed to determine the effect of a drug-induced apoptosis assay results on treatments planned by oncologists. METHODS: Purified cancer cells from patient biopsies were placed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc405bb31f253568fe27b8970ea0a0e3
https://doi.org/10.1002/cncr.27444
https://doi.org/10.1002/cncr.27444
Autor:
Emery M. Salom, Allan Hallquist, Karl Rogers, Swapnil Rajurkar, Dirk C. Davidson, Pat Whitworth, Cary A. Presant
Publikováno v:
Oncology Issues. 25:18-23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9683ddcaf6a81d5693601fe7f28a7fb
https://doi.org/10.1080/10463356.2010.11883494
https://doi.org/10.1080/10463356.2010.11883494
Publikováno v:
Journal of Oncology Practice. 7:100-102
Purpose: With the advent of newer cancer therapies (eg, biologic and cytotoxic), treatment is becoming increasingly expensive for patients with cancer. Patients enrolled in Medicare and commercial insurance plans often have large copay requirements w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b9e81d51f8fb0cd0a8e3901c850ba4d
https://doi.org/10.1200/jop.2010.000112
https://doi.org/10.1200/jop.2010.000112